| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/16/2004 | WO2004035005A3 Three layer tear formulation |
| 09/16/2004 | WO2004030631A3 Anti-cancer and anti-infectious disease compositions and methods for using same |
| 09/16/2004 | WO2004028459A3 Piperidine derivatives |
| 09/16/2004 | WO2004026295A9 Use of skin-protecting substances |
| 09/16/2004 | WO2004019889A3 Inhibitors of post-amadori advanced glycation end products |
| 09/16/2004 | WO2004012655A3 Anti-microbial compositions and methods of using same |
| 09/16/2004 | WO2004004646A3 O-derivatized nocathiacin derivatives |
| 09/16/2004 | WO2003105776A3 ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE |
| 09/16/2004 | WO2003105666A3 Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
| 09/16/2004 | WO2003104257A3 Protease inhibitors |
| 09/16/2004 | WO2003104253A3 9-alpha-substituted estratrienes as selectively active estrogen |
| 09/16/2004 | WO2003096989A3 Anti tubercular drug: compositions and methods |
| 09/16/2004 | WO2003094839A3 Pyrimidinone compounds, compositions and methods |
| 09/16/2004 | WO2003092586A3 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 09/16/2004 | WO2003091207A3 Method of preparing amine stereoisomers |
| 09/16/2004 | WO2003088918A3 PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE |
| 09/16/2004 | WO2003073989A3 Nucleoside 5'-monophosphate mimics and their prodrugs |
| 09/16/2004 | WO2003072553A8 N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials |
| 09/16/2004 | WO2003066063A8 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist |
| 09/16/2004 | WO2003066004A3 Therapeutic compounds |
| 09/16/2004 | WO2003065971A3 Non-myeloablative tolerogenic treatment with tyrphostins |
| 09/16/2004 | WO2003062265A3 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 09/16/2004 | WO2003057176A3 Porphyrins with virucidal activity |
| 09/16/2004 | WO2003053457A8 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 09/16/2004 | WO2003045318A3 Manipulation of cytokine levels using cd83 gene products |
| 09/16/2004 | WO2003045228A9 Methods for treating autoimmune disorders, and reagents related thereto |
| 09/16/2004 | WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies |
| 09/16/2004 | WO2003028729A3 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 09/16/2004 | WO2002100827A3 Method for increasing the survival of dopamine secreting cells |
| 09/16/2004 | WO2002099043A8 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 09/16/2004 | WO2002064093A8 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| 09/16/2004 | US20040181429 Method and system for administering a drug |
| 09/16/2004 | US20040181089 Drugs and methods of administering forming with crystallization and precipitation for antidiabetic agents |
| 09/16/2004 | US20040181073 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils |
| 09/16/2004 | US20040181069 modulators of the monoamine receptors, in particular the serotonin, dopamine and norepinephrine receptors, and the biogenic amine transporters for serotonin, dopamine and norepinephrine; |
| 09/16/2004 | US20040181064 Bicyclic modulators of androgen receptor function |
| 09/16/2004 | US20040181063 such as 1-C-(5-N-benzyloxymethyl-4-methoxy pyrrolo[3,2-d]pyrimidin-7-yl)-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol; potent inhibitors of purine nucleoside phosphorylase and useful for suppressing T-cell function and/or treating and/or preventing infections caused by protozoan parasites |
| 09/16/2004 | US20040181062 Benzimidazole cyclooxygenase-2 inhibitor |
| 09/16/2004 | US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181045 Antisense nucleotide sequences for treatment, diagnosis and prevention of viral and autoimmune disorders |
| 09/16/2004 | US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 09/16/2004 | US20040180968 Methods for the treatment and prevention of pancreatitis and for induction of liver regeneration |
| 09/16/2004 | US20040180967 A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction |
| 09/16/2004 | US20040180966 Enantiomers of N-desmethyl venlafaxine |
| 09/16/2004 | US20040180965 Benzydamine hydrochloride, polyoxyalkylene block copolymer, propylene glycol, in water having a pH value in the range of about 3.5 to 7 |
| 09/16/2004 | US20040180964 anti-obestic activity; Neuropeptide Y antagonist |
| 09/16/2004 | US20040180963 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 09/16/2004 | US20040180962 Dosage forms having prolonged active ingredient release |
| 09/16/2004 | US20040180961 poorly water-soluble aceclofenac, a polymeric base selected from the group consisting of polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, glycerolmonostearate, carbamer and poloxamer, and a surfactant |
| 09/16/2004 | US20040180959 --title-- |
| 09/16/2004 | US20040180958 Method of treatment |
| 09/16/2004 | US20040180957 rescuing damaged nerve cells; kits and instructions for administering |
| 09/16/2004 | US20040180956 calcium salt is calcium trifluoroacetate; to prepare medicaments with cytotoxic and antitumoral activity |
| 09/16/2004 | US20040180955 to establish a low circulating concentration of suramin in the patient of below about 200 mu, then administering cytotoxic agent |
| 09/16/2004 | US20040180953 B form is the most thermodynamically stable form at room temperature; a purer and more homogeneous product is produced and recrystallization is advantageously carried out by initiating with a small amount of the product |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180951 Mixture of plant extracts; fractionation |
| 09/16/2004 | US20040180950 4,5-dithio substituted coumarin derivatives, and coumarin dimers; the treatment of hepatitis C virus |
| 09/16/2004 | US20040180949 conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue |
| 09/16/2004 | US20040180948 2-Amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors |
| 09/16/2004 | US20040180947 Sulfonamide compounds and pharmaceutical use thereof |
| 09/16/2004 | US20040180946 Phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation |
| 09/16/2004 | US20040180944 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 09/16/2004 | US20040180943 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis |
| 09/16/2004 | US20040180940 Substituted anilide ligands for the thyroid receptor |
| 09/16/2004 | US20040180939 Acetyl 2-hydroxy-1, 3-diaminoalkanes |
| 09/16/2004 | US20040180937 Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 09/16/2004 | US20040180936 having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species; inflammatory and immunological diseases; disorders of the central or peripheral nervous system |
| 09/16/2004 | US20040180934 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists |
| 09/16/2004 | US20040180932 Benzothiophenes, formulations containing same, and methods |
| 09/16/2004 | US20040180931 Methods for treating Parkinson's disease |
| 09/16/2004 | US20040180928 Process for the preparation of dexmethylphenidate hydrochloride |
| 09/16/2004 | US20040180923 obesity, diabetes, male sexual dysfunction, and female sexual dysfunction |
| 09/16/2004 | US20040180922 Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 09/16/2004 | US20040180921 Nitrogen compounds such as 2-benzofuran-2-yl-imidazo(1,2-a) pyridine administered as g protein coupled receptor antagonists for prophylaxis of psychological and neurodegenerative disorders, and as analgesics |
| 09/16/2004 | US20040180920 Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders |
| 09/16/2004 | US20040180919 immune response modifier imiquimod; certain immune response modifier (IRM) compounds can be used to improve skin quality |
| 09/16/2004 | US20040180918 PDE 4 inhibitor (cilomilast) and an anticholinergic agent (tiotropium); asthma; copd |
| 09/16/2004 | US20040180917 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same |
| 09/16/2004 | US20040180916 Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists |
| 09/16/2004 | US20040180915 Methadone-containing compositions for parenteral administration and method of use thereof |
| 09/16/2004 | US20040180914 5-Cyano-2-aminopyrimidine derivatives |
| 09/16/2004 | US20040180912 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable |
| 09/16/2004 | US20040180911 for the treatment of a proliferative disease, such as a tumor |
| 09/16/2004 | US20040180910 Heterocycle carboxamides as antiviral agents |
| 09/16/2004 | US20040180908 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol |
| 09/16/2004 | US20040180907 for use in fertility regulating therapies |
| 09/16/2004 | US20040180906 Anti-inflammatory medicaments |
| 09/16/2004 | US20040180905 for treating cancer and fibrotic diseases |
| 09/16/2004 | US20040180904 Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts |
| 09/16/2004 | US20040180903 Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| 09/16/2004 | US20040180901 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 09/16/2004 | US20040180900 Therapeutic composition for repairing chondropathy |
| 09/16/2004 | US20040180899 tyrosine kinase inhibitors |
| 09/16/2004 | US20040180898 chemical reduction reaction |
| 09/16/2004 | US20040180897 anticarcinogenic agents |
| 09/16/2004 | US20040180896 P38 inhibitors and methods of use thereof |
| 09/16/2004 | US20040180895 Use of a pyridazinone derivative |
| 09/16/2004 | US20040180894 Benzamide inhibitors of the P2X7 receptor |